ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY

N/A

Manufactured by The Procter & Gamble Manufacturing Company

144 FDA adverse event reports analyzed

Last updated: 2026-04-15

About ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY

ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by The Procter & Gamble Manufacturing Company. The most commonly reported adverse reactions for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY include RASH, APPLICATION SITE PAIN, APPLICATION SITE RASH, DYSPNOEA, ERYTHEMA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY.

Top Adverse Reactions

RASH8 reports
APPLICATION SITE PAIN4 reports
APPLICATION SITE RASH4 reports
DYSPNOEA4 reports
ERYTHEMA4 reports
HEADACHE4 reports
HYPERSENSITIVITY4 reports
PRURITUS4 reports
RASH ERYTHEMATOUS3 reports
APPLICATION SITE IRRITATION2 reports
ASTHENIA2 reports
DERMAL CYST2 reports
FURUNCLE2 reports
LACRIMATION INCREASED2 reports
PAIN2 reports
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE2 reports
PURULENT DISCHARGE2 reports
RASH MACULAR2 reports
RHINORRHOEA2 reports
SKIN BURNING SENSATION2 reports
SKIN IRRITATION2 reports
SKIN SWELLING2 reports
SKIN WARM2 reports
ABNORMAL FAECES1 reports
ABSCESS1 reports
ABSCESS SOFT TISSUE1 reports
ACNE1 reports
ALOPECIA1 reports
ANAPHYLACTIC REACTION1 reports
ANTICOAGULATION DRUG LEVEL ABNORMAL1 reports
APPLICATION SITE DERMATITIS1 reports
APPLICATION SITE ERYTHEMA1 reports
APPLICATION SITE EXFOLIATION1 reports
APPLICATION SITE PRURITUS1 reports
APPLICATION SITE VESICLES1 reports
ASTHMA1 reports
AXILLARY PAIN1 reports
BACTERIAL INFECTION1 reports
BLISTER1 reports
BLOOD PRESSURE INCREASED1 reports
BLOODY DISCHARGE1 reports
BREAST CANCER STAGE I1 reports
BREAST CYST1 reports
BURNING SENSATION1 reports
BURNS SECOND DEGREE1 reports
CELLULITIS1 reports
CEREBROVASCULAR ACCIDENT1 reports
CERVIX CARCINOMA1 reports
CERVIX HAEMORRHAGE UTERINE1 reports
CHEMICAL BURN OF SKIN1 reports
CHEST PAIN1 reports
CHILLS1 reports
CHRONIC KIDNEY DISEASE1 reports
CONDITION AGGRAVATED1 reports
COUGH1 reports
DEFORMITY1 reports
DEHYDRATION1 reports
DERMATITIS1 reports
DERMATITIS ALLERGIC1 reports
DERMATITIS CONTACT1 reports
DRUG INEFFECTIVE1 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION1 reports
DYSARTHRIA1 reports
DYSGEUSIA1 reports
EXPIRED PRODUCT ADMINISTERED1 reports
EYE PAIN1 reports
FATIGUE1 reports
FEELING ABNORMAL1 reports
GASTROENTERITIS1 reports
HAIR COLOUR CHANGES1 reports
HORMONE RECEPTOR POSITIVE BREAST CANCER1 reports
HYPERHIDROSIS1 reports
HYPOAESTHESIA ORAL1 reports
IMMUNE SYSTEM DISORDER1 reports
INFECTION1 reports
INVASIVE DUCTAL BREAST CARCINOMA1 reports
LYMPHOMA1 reports
MACULE1 reports
MEMORY IMPAIRMENT1 reports
MENTAL IMPAIRMENT1 reports
METAL POISONING1 reports
METASTASES TO LYMPH NODES1 reports
MUSCLE TWITCHING1 reports
NAUSEA1 reports
NERVOUSNESS1 reports
OCULAR HYPERAEMIA1 reports
OFF LABEL USE1 reports
PAIN OF SKIN1 reports
PARKINSON^S DISEASE1 reports
PHARYNGEAL HYPOAESTHESIA1 reports
PNEUMONIA1 reports
PRODUCT CONTAMINATION CHEMICAL1 reports
PRODUCT DIFFICULT TO REMOVE1 reports
PRODUCT FORMULATION ISSUE1 reports
PRODUCT ODOUR ABNORMAL1 reports
PRODUCT QUALITY ISSUE1 reports
PRODUCT USE ISSUE1 reports
PYREXIA1 reports
RASH GENERALISED1 reports
REACTION TO DRUG EXCIPIENTS1 reports

Report Outcomes

Out of 37 classified reports for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY:

Serious 73.0%Non-Serious 27.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female18 (51.4%)
Male17 (48.6%)

Reports by Age

Age 253 reports
Age 312 reports
Age 482 reports
Age 592 reports
Age 602 reports
Age 161 reports
Age 201 reports
Age 211 reports
Age 221 reports
Age 261 reports
Age 281 reports
Age 301 reports
Age 361 reports
Age 371 reports
Age 391 reports
Age 411 reports
Age 431 reports
Age 471 reports
Age 501 reports
Age 511 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY?

This profile reflects 144 FDA FAERS reports that mention ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY?

Frequently reported terms in FAERS include RASH, APPLICATION SITE PAIN, APPLICATION SITE RASH, DYSPNOEA, ERYTHEMA, HEADACHE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY?

Labeling and FAERS entries often list The Procter & Gamble Manufacturing Company in connection with ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.